Working… Menu

Advanced or Recurrent Ovarian, Cervical, and Endometrial Cancer Treated With SHetA2 (Okgyn1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04928508
Recruitment Status : Not yet recruiting
First Posted : June 16, 2021
Last Update Posted : October 20, 2021
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Oklahoma

Brief Summary:
The purpose of this research is to test the safety of the study drug (SHetA2) and see what effects (good and bad) this drug has on patients with recurrent cervical, ovarian, or endometrial cancer.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Endometrial Cancer Cervix Cancer Drug: SHetA2 Phase 1

Detailed Description:
SHetA2 capsules will be given twice a day, every day in 21-day blocks of time. Each block of time is called a cycle. The cycle will be repeated until the patient or doctor no longer feel participation in the study is right for the patient. There will be lab tests and examinations to monitor the patients progress. We expect that taking part in this research will last up to three years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Trial of SHetA2 in Patients With Advanced or Recurrent Ovarian, Cervical, and Endometrial Cancer
Estimated Study Start Date : November 2021
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : July 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: SHetA2 capsule
SHetA2 (oral, BID) within a 21-days cycle
Drug: SHetA2

SHetA2 orally in the form of 50 mg capsules. Four dose levels will be evaluated:

5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg

Other Name: NSC 726189

Primary Outcome Measures :
  1. Number of dose-limiting toxicities of treatment with SHetA2 [ Time Frame: 21 days ]
  2. Dosage Recommendation for Phase 2 [ Time Frame: 21 days ]

Secondary Outcome Measures :
  1. Rate of objective response [ Time Frame: up to three years ]
  2. Median duration of response [ Time Frame: up to three years ]
  3. Rate of disease control [ Time Frame: up to three years ]
  4. Median progression free survival [ Time Frame: up to three years ]
  5. Median overall survival [ Time Frame: up to three years ]
  6. Incidence of adverse events [ Time Frame: up to three years ]
    safety and tolerability of SHetA2 using Common Terminology Criteria for Adverse Events (CTCAE) v.5.0

  7. Tmax of PK plasma concentration [ Time Frame: 24 hours ]
  8. Cmax of PK plasma concentration [ Time Frame: 24 hours ]
  9. AUC of PK plasma concentration [ Time Frame: 24 hours ]
  10. t1/2 of PK plasma concentration [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma which is considered platinum resistant (recurrence < 6 months from last platinum treatment or for whom platinum therapy is no longer considered appropriate). Histologic documentation of the original primary tumor is required via the pathology report.

NOTE: Patients with the following histologic ovarian epithelial cell types are eligible:

High grade serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise specified (N.O.S.).


Patients with recurrent cervical cancer and who have progressed following or refused platinum based therapy. Squamous, adenocarcinomas and adenosquamous cancers are eligible. Other histologies will be considered if HPV related.


Patients with histologically-documented carcinoma of the endometrium, including endometrioid, serous, mixed adenocarcinoma, clear-cell carcinoma, or carcinosarcoma. Evidence that the endometrial cancer is advanced, recurrent, or persistent and has relapsed or is refractory to curative therapy or established treatments.

Patients must have adequate:

  • Bone marrow function as defined per protocol
  • Renal function as defined per protocol
  • Hepatic function as defined per protocol
  • International normalized ratio (INR) or prothrombin time (PT) ≤1.5x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
  • Activated partial thromboplastin time (aPTT) ≤1.5x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  • Neurologic function: Neuropathy (sensory and motor) less than or equal to Grade 1. Patients should be free of active infection requiring parenteral antibiotics or a serious uncontrolled medical illness or disorder within four weeks of study entry.
  • Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration. Continuation of hormone replacement therapy is permitted.
  • Patients must have a performance status score of 0-2 by Eastern Cooperative Group (ECOG) criteria.
  • Patients of childbearing potential must have a negative pregnancy test prior to the study entry and be practicing an effective form of contraception. If applicable, patients must discontinue breastfeeding prior to study entry.
  • Patients must have satisfactory results for the baseline laboratory analyses and diagnostic procedures as specified in the protocol
  • Patients must have signed an IRB-approved informed consent and authorization permitting release of personal health information.
  • Patients must be at least 18 years old.
  • Patients in all cohorts must have a fresh pre-treatment tumor biopsy.
  • Patients must be willing to have fresh biopsy taken post-Cycle 1 treatment
  • Life expectancy of at least 3 months.
  • Patients must be able to take oral medications.
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

Exclusion Criteria:

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to SHetA2.
  • A diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  • Patients receiving treatment for active autoimmune disease. "Active" refers to any condition currently requiring therapy. Examples of autoimmune disease include systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis. (note if steroid use is <10mg/day prednisolone equivalent and patient has stable symptoms they may be allowed on study with discussion with the medical monitor)
  • Patients with a prior or concurrent malignancy whose natural history or treatment does have the potential to interfere with the safety or efficacy assessment of the investigational regimen are NOT eligible for this trial.
  • Known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid [HCV RNA] [qualitative] is detected). Ongoing systemic bacterial, fungal, or viral infection; known human immunodeficiency virus (HIV) infection with positive viral load or acquired immunodeficiency syndrome (AIDS)-related illness. Patients with HIV and a negative viral load are allowed on study.
  • Patients with concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy.
  • Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study.

NOTE: Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging (using the identical imaging modality for each assessment, either magnetic resonance imaging [MRI] or computed tomography [CT] scan) for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability

  • Patients taking concomitant therapy with any of the following: other non-study cytotoxic chemotherapy; other investigational therapies.
  • Prior bone marrow/hematopoietic stem cell transplantation
  • History of solid organ, bone marrow, or progenitor cell transplantation
  • History of major surgical procedure within 28 days prior to start of study treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04928508

Layout table for location contacts
Contact: Ingrid Block 1-405-271-8777
Contact: Lead Gynecology Oncology Nurse 1-405-271-8777

Layout table for location information
United States, Oklahoma
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73104
Contact: Ingrid Block    405-271-8777   
Contact: Lead Gynecology Oncology Nurse    1-405-271-8777   
Principal Investigator: Kathleen Moore, MD         
Sponsors and Collaborators
University of Oklahoma
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Kathleen Moore, MD Stephenson Cancer Center
Layout table for additonal information
Responsible Party: University of Oklahoma Identifier: NCT04928508    
Other Study ID Numbers: Okgyn1
R01CA196200 ( U.S. NIH Grant/Contract )
First Posted: June 16, 2021    Key Record Dates
Last Update Posted: October 20, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Uterine Cervical Neoplasms
Neoplasms by Site
Genital Neoplasms, Female
Urogenital Neoplasms
Uterine Neoplasms
Uterine Diseases
Uterine Cervical Diseases